Drew Amorosi is a Senior Staff Writer at Healio. He focuses on a range of themes within medicine and healthcare, including medical specialties, alternative medicine, and the healthcare system, while also addressing social issues such as racial injustice and the impact of AI. Drew's work has been featured in various reputable outlets, highlighting his commitment to informing the public on crucial health-related topics.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Drew Amorosi's coverage primarily focuses on healthcare and pharmaceuticals, often citing data and press releases. He may be interested in pitches related to new scientific research, breakthrough treatments, or innovative therapies within the field of cancer treatment and precision medicine.
Given his focus on racial disparities in cancer treatment and specific diseases such as breast cancer, sickle cell disease, multiple myeloma, etc., Drew would likely welcome pitches that highlight efforts to address these disparities or advancements in treating these conditions.
As there is no specified geographic focus for Drew's articles, sources with a global perspective or those involved in international medical studies could be relevant for reaching out to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Drew Amorosi, Cassandra Jenkins
A real-world study of patients with overweight or obesity and heart failure demonstrated that initiation of semaglutide 2.4 mg corresponded with a mean total medical cost reduction of $6,512 during a 1-year follow-up period.
By: Emma Bascom, Drew Amorosi
In March, the CDC announced that patients with COVID-19 who are showing certain signs of improvement no longer had to isolate for 5 days.
By: Andrew Drew, Drew Amorosi
Researchers found “measurable concentrations” of 16 metals, including toxic lead, in 60 tampon samples tested during an analysis, according to study results published in Environment International
By: Emma Bascom, Drew Amorosi
In early August, the FDA approved neffy epinephrine nasal spray to treat emergent type 1 allergic reactions in patients who weigh at least 66 pounds.
By: Yoav Ben-Ari, Drew Amorosi, Andrew Drew
ORLANDO — In this video, a presenter at the AIMed24 Annual Meeting talks about growing cybersecurity threats in health care and what strategies could effectively address them.
By: Cassandra Jenkins, Drew Amorosi
Researchers found that the presence of eosinophilic inflammation in the airway predicted asthma development among children aged 5 years and younger with treatment-refractory wheeze.
By: Moira Mahoney, Drew Amorosi
According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the previous decade.
By: Moira Mahoney, Drew Amorosi
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according to a presentation at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease.
By: Moira Mahoney, Drew Amorosi
Alcohol consumption may trigger worse allergic reactions in patients with nut allergies, according to a study published in International Archives of Allergy and Immunology
By: Cassandra Jenkins, Drew Amorosi
A suspected Marburg virus outbreak in the Kagera region of Tanzania has been linked to nine suspected cases and eight deaths, according to WHO.
(833) 317-6278 
